NEW YORK, Sept. 20 – Eli Lilly has formed a new $75 million venture capital fund, Lilly BioVentures, that will invest in early-stage biotechnology companies, Lilly said Thursday.  

The venture capital group will make initial investments of up to $5 million in companies developing new biotechnology or biopharmaceutical technologies, and companies developing new or improved platforms for drug discovery, Lilly said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.